文献速递妇科

美国参保女性宫颈癌筛查实践及相关下游异常与操作的时间趋势

Temporal Trends in Cervical Cancer Screening Practices and Associated Downstream Abnormalities and Procedures Among Women With Insurance in the United States.
PubMed 文献 · Obstet Gynecol · 2022-06-07

该研究基于2008至2019年IBM MarketScan数据库,纳入18-64岁拥有商业保险或医疗补助保险的女性,分析宫颈癌筛查率及下游异常细胞学/组织学结果、阴道镜和切除操作的年率变化。结果显示商业保险女性筛查率从42.6%降至29.4%,医疗补助保险女性从27.9%降至12.4%(均P<.001);已筛查人群中异常结果和阴道镜率上升,而符合条件人群中相应率下降。

要点

  • 2008至2019年商业保险女性筛查率由42.6%降至29.4%,医疗补助保险女性由27.9%降至12.4%(均P<.001)。
  • 商业保险女性中细胞学检查使用率由79.4%降至38.9%,联合检测由20.1%升至59.6%(P<.001)。
  • 每千名已筛查女性中异常组织学和细胞学结果率由96升至119,阴道镜率由33升至42(均P<.001)。

核心结论

  • 人乳头瘤病毒检测已快速融入宫颈癌筛查,在已筛查女性中与下游异常和操作增加的趋势相关,但在人群水平呈下降趋势。

研究设计与样本

  • 使用IBM MarketScan数据库识别2008至2019年18-64岁拥有商业保险或医疗补助保险的女性。
  • 分析总体及按检测类型(细胞学、联合检测或原发人乳头瘤病毒检测)的年度筛查率。
  • 检查下游异常细胞学和组织学结果、阴道镜及切除操作,并分别报告持续参保的符合条件人群和接受筛查人群中的率。
  • 使用χ2检验和Spearman相关分析比较检测和结局随时间的变化。

主要发现

  • 2008至2019年年度筛查患病率在商业保险女性中从42.6%降至29.4%(P<.001),在医疗补助保险女性中从27.9%降至12.4%(P<.001)。
  • 商业保险女性队列中细胞学使用率从79.4%降至38.9%,联合检测从20.1%升至59.6%(P<.001)。
  • 每千名已筛查女性中异常组织学和细胞学结果率从96升至119(P<.001),阴道镜率从33升至42(P<.001);切除操作保持相对稳定。
  • 每千名符合条件女性中异常组织学和细胞学结果率从41降至35(P<.001),阴道镜率从14降至12,切除操作从3降至2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine temporal trends in cervical cancer screening practices and associated downstream abnormalities and procedures. METHODS: Women aged 18-64 years with commercial insurance or Medicaid insurance from 2008 to 2019 were identified using the IBM MarketScan databases. The annual rates of screening overall and by type of test (cytology, co-testing, or primary human papillomavirus testing) were examined. Downstream abnormal cytologic and histologic test results, colposcopies, and excisional procedures were examined, and rates were reported for the population of eligible patients with continuous insurance and for those who underwent screening. Changes over time in testing and outcomes were compared using χ2 tests and Spearman's correlation. RESULTS: From 2008 to 2019, the annual screening prevalence decreased from 42.6% to 29.4% in women with commercial insurance (P<.001) and from 27.9% to 12.4% among women with Medicaid insurance (P<.001). In the cohort of women with commercial insurance, cytology usage decreased from 79.4% to 38.9% and co-testing increased from 20.1% to 59.6% (P<.001). Per 1,000 women screened, the rate of abnormal histologic and cytologic test results rose from 96 to 119 (P<.001) and colposcopies rose from 33 to 42 (P<.001); excisional procedures remained relatively constant. Per 1,000 eligible women, the rate of abnormal histologic and cytologic test results decreased from 41 to 35 (P<.001), colposcopies declined from 14 to 12, and excisional procedures decreased from 3 to 2. CONCLUSION: Human papillomavirus testing has been rapidly incorporated into cervical cancer screening and is associated with an increasing trend of downstream abnormalities and procedures among screened women but a declining trend at the population level.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Liao L, Chen L, Gockley A, et al. Temporal Trends in Cervical Cancer Screening Practices and Associated Downstream Abnormalities and Procedures Among Women With Insurance in the United States. Obstet Gynecol. 2022. PMID: 35849456. doi:10.1097/AOG.0000000000004838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。